Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immutep Ltd

IMM.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: HOLD

Last Close

$0.04

▲ +1.89%

Market Cap $56.89M · Vol 4.42M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$56.89M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

+5.44%

YoY

RSI (14)

73.33

Momentum

Beta

2.40

vs Market

52W High

$0.34

88.01% below

52W Low

$0.02

97.83% above

Volume

4.42M

Avg 7.30M

P/B

2.44

Price-to-book

ROE

-35.96%

Return on equity

Free Float

96.98%

Public shares

Shariah Compliance8 STANDARDS

✗ Immutep Ltd (IMM.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMM.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.89%

+12.50%

-5.26%

-86.15%

YTD

-86.99%

-78.40%

-77.83%

-88.35%

Financials & Valuation

TTM · Annual

Total Revenue	$39.55K
Net Income	$-40,423,600.00
Revenue Growth (YoY)	+17,610.17%
Gross Margin	100.00%
Operating Margin	-116,466.06%
Net Profit Margin	-102,221.61%
ROE	-35.96%
ROA · ROIC	-34.27% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5,813.68
P/B	2.44
P/FCF	N/A
EPS Growth	+5.44%
Outstanding Shares	1.47B

Technical Indicators

50-Day SMA	$0.04
200-Day SMA	$0.13
RSI (14)	73.33
Beta	2.40
52-Week High	$0.34
52-Week Low	$0.02

Volume Today	4.42M
Avg Daily Volume (30D)	7.30M
Relative Volume	0.61x
Volatility (10D)	38.68
Volatility (30D)	45.17
Free Float	96.98%

Analyst Consensus

HOLD

Current Price $0.04

Mean Target $0.65

52W Low$0.02 52W High$0.34

Current

Target

$0.02 $0.34

Current Analyst target

+1,577.95% upside potential · 6 analysts

Identifiers

ExchangeASX

FIGIBBG002WD6TP4

ISINAU000000IMM6

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 29, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.